Table 1.
Baseline patient characteristics in the pre- and post-propensity score matching cohort
| Characteristic | Before propensity score matching |
After propensity score matching |
||||
|---|---|---|---|---|---|---|
| CRT (n=380) | NCT (n=188) | p-value | CRT (n=150) | NCT (n=150) | p-value | |
| Sex | ||||||
| Male | 266 (70.0) | 144 (76.6) | 0.099 | 111 (74.0) | 111 (74.0) | > 0.999 |
| Female | 114 (30.0) | 44 (23.4) | 39 (26.0) | 39 (26.0) | ||
| Age | ||||||
| Median (range, yr) | 52 (19-86) | 50 (20-73) | 0.223 | 51.5 (19-77) | 50 (19-72) | 0.648 |
| Mean±SD | 51.4±13.1 | 50.0±12.1 | 50.8±13.2 | 50.5±11.6 | ||
| ECOG PS | ||||||
| 0 | 65 (17.1) | 34 (18.1) | 0.539 | 27 (18.0) | 25 (16.7) | 0.963 |
| 1 | 303 (79.7) | 151 (80.3) | 119 (79.3) | 122 (81.3) | ||
| 2 | 12 (3.2) | 3 (1.6) | 4 (2.7) | 3 (2.0) | ||
| WHO histology | ||||||
| I | 77 (20.3) | 17 (9.0) | < 0.001 | 15 (10.0) | 17 (11.3) | 0.502 |
| IIa | 108 (28.4) | 75 (39.9) | 59 (39.3) | 58 (38.7) | ||
| IIb | 187 (49.2) | 84 (44.7) | 70 (46.7) | 71 (47.3) | ||
| Not classified | 8 (2.1) | 12 (6.4) | 6 (4.0) | 4 (2.7) | ||
| T stage | ||||||
| 1 | 95 (25.0) | 54 (28.7) | 0.308 | 38 (25.3) | 40 (26.7) | 0.389 |
| 2 | 102 (26.8) | 39 (20.7) | 34 (22.7) | 34 (22.7) | ||
| 3 | 86 (22.6) | 39 (20.7) | 36 (24.0) | 35 (23.3) | ||
| 4 | 97 (25.5) | 56 (29.8) | 42 (28.0) | 41 (27.3) | ||
| N stage | ||||||
| 0 | 44 (11.6) | 16 (8.5) | 0.366 | 15 (10.0) | 13 (8.7) | 0.410 |
| 1 | 104 (27.4) | 50 (26.6) | 42 (28.0) | 41 (27.3) | ||
| 2 | 172 (45.3) | 98 (52.1) | 71 (47.3) | 75 (50.0) | ||
| 3 | 60 (15.8) | 24 (12.8) | 22 (14.7) | 21 (14.0) | ||
| AJCC stage | ||||||
| II | 38 (10.0) | 13 (6.9) | 0.480 | 14 (9.3) | 12 (8.0) | 0.914 |
| III | 194 (51.1) | 99 (52.7) | 77 (51.3) | 79 (52.7) | ||
| IV | 148 (38.9) | 76 (40.4) | 59 (39.3) | 59 (39.3) | ||
| Hospital size | ||||||
| Large | 264 (69.5) | 104 (55.3) | 0.001 | 97 (64.7) | 93 (62.0) | 0.637 |
| Small | 116 (30.5) | 84 (44.7) | 53 (35.3) | 57 (38.0) | ||
| RT method | ||||||
| Non-IMRT | 231 (60.8) | 63 (33.5) | < 0.001 | 52 (34.7) | 57 (38.0) | 0.456 |
| IMRT | 149 (39.2) | 125 (66.5) | 98 (65.3) | 93 (62.0) | ||
| CRT regimen | ||||||
| Cisplatin alone | 322 (84.7) | 159 (84.6) | 0.883 | 131 (87.3) | 126 (84.0) | 0.411 |
| Combined | 58 (15.3) | 29 (15.4) | 19 (12.7) | 24 (16.0) | ||
| NCT regimen | ||||||
| FP | - | 36 (19.1) | N/A | - | 32 (21.3) | N/A |
| F or P+taxane | - | 64 (34.0) | - | 61 (40.7) | ||
| FP+taxane | - | 78 (41.4) | - | 48 (32.0) | ||
| Other | - | 10 (5.3) | - | 9 (6.0) | ||
Values are presented as number (%) unless otherwise indicated. CRT, concurrent chemoradiotherapy arm; NCT, neoadjuvant chemotherapy arm; SD, standard deviation; ECOG PS, Eastern Cooperative Oncology Group performance status; WHO, World Health Organization; AJCC, American Joint Committee on Cancer; RT, radiation therapy; IMRT, intensity-modulated radiotherapy; F, 5-fluorouracil; P, cisplatin; N/A, not assessed.